Tata Chemicals swung to a sharp Q4FY26 net loss, driven by large impairment charges and weak global pricing, with margins turning negative. Revenue edged down about 2%, while cash flows weakened. The company noted core performance improved before exceptional items, but difficult market conditions kept earnings under pressure.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
